Market Overview:
The global benign prostatic hyperplasia (BPH) medication market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of BPH, rising geriatric population, and technological advancements in the field of BPH medications. Based on type, the global benign prostatic hyperplasia (BPH) medication market is segmented into 5-alpha-reductase inhibitors, beta-blockers, botanicals and traditional Chinese medicine. The 5-alpha reductase inhibitors segment is expected to account for the largest share of the global BPH medication market in 2018 owing to its high efficacy and safety profile. Based on application, the hospital pharmacies segment is expected to account for a larger share of the global BPH medication market in 2018 followed by retail pharmacies and online pharmacies segments respectively.
 Medication Industry Outlook.svg)
Product Definition:
Benign prostatic hyperplasia (BPH) medication is a type of drug that is used to treat an enlarged prostate. This type of medication can help to improve symptoms such as difficulty urinating, a weak urine stream, and the need to urinate frequently. BPH medications may also help to reduce the risk of developing acute urinary retention or bladder stones.
5-Alpha-Reductase Inhibitors:
5-ALPHA-REDUCTASE INHIBITORS, it's usage.
The global 5 alpha -reductase inhibitors, it's usage and growth factor in BPH medication market size was valued at USD 2.6 billion in 2015.
Beta-Blockers:
Beta-blockers are a class of drugs that help to decrease the heart rate and lower the blood pressure. They are used in patients with high risk for cardiovascular diseases, including BPH. The use of beta-blockers helps to reduce the symptoms such as urinary urgency, urinary frequency, and nocturia in men with BPH.
Application Insights:
The application segment includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacy held the largest market share in 2017 owing to the availability of drugs in stock for dispensing. Retail pharmacy is expected to grow at a rapid pace over the forecast period due to increasing awareness among individuals regarding their health conditions and treatment options. The use of these medications by men with BPH at a younger age group is expected to boost growth during the forecast period.
Botanicals are widely used for benign prostatic hyperplasia (BPH) treatment as they have no side effects and are relatively cheaper than other types of medication available in market.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of major players, high patient awareness levels coupled with easy access to healthcare services. Moreover, an increase in government initiatives and educational programs about BPH treatment options is expected to fuel growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income and improving healthcare infrastructure especially in emerging countries such as China and India. Furthermore, increasing prevalence of Benign Prostatic Hyperplasia (BPH) among aging population will drive regional growth over the forecast years (Figure 1).
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive the demand for BPH medications in the coming years.
- Growing awareness about BPH and its treatment options: There is growing awareness among people about BPH and its treatment options, which is likely to boost the demand for these medications in the near future.
- Rising incidence of prostate cancer: The incidence of prostate cancer is on the rise globally, which is expected to fuel the demand for BPH medications in the coming years.
- Technological advancements: The development of new and innovative technologies has led to better diagnosis and treatment of BPH, thereby propelling market growth over the forecast period. 5) Availability of generic versions of branded drugs: The availability of generic versions of branded drugs at lower prices has made these medications more affordable for patients, thus driving market growth over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Benign Prostatic Hyperplasia (BPH) Medication Market Research Report
By Type
5-Alpha-Reductase Inhibitors, Beta-Blockers, Botanicals and Traditional Chinese Medicine
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Bayer HealthCare, Bristol-Myers Squibb, Valeant Pharmaceuticals, Endo Pharmaceuticals, Foresee Pharmaceuticals, Merck, Novartis, Advaxis, Teva Pharmaceutical Industries, Urologixs, Agennix, ANI Pharmaceuticals, BHR Pharma, Boehringer Ingelheim, Sanpower Group, Eisai, Ferring, IO THERAPEUTICS, LIDDS, Madrigal Pharmaceuticals, Nymox Pharmaceutical, Spectrum Pharmaceuticals, Takeda Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Benign Prostatic Hyperplasia (BPH) Medication Market Report Segments:
The global Benign Prostatic Hyperplasia (BPH) Medication market is segmented on the basis of:
Types
5-Alpha-Reductase Inhibitors, Beta-Blockers, Botanicals and Traditional Chinese Medicine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- Eli Lilly
- GlaxoSmithKline
- Sanofi
- ADC Therapeutics
- Bayer HealthCare
- Bristol-Myers Squibb
- Valeant Pharmaceuticals
- Endo Pharmaceuticals
- Foresee Pharmaceuticals
- Merck
- Novartis
- Advaxis
- Teva Pharmaceutical Industries
- Urologixs
- Agennix
- ANI Pharmaceuticals
- BHR Pharma
- Boehringer Ingelheim
- Sanpower Group
- Eisai
- Ferring
- IO THERAPEUTICS
- LIDDS
- Madrigal Pharmaceuticals
- Nymox Pharmaceutical
- Spectrum Pharmaceuticals
- Takeda Pharmaceuticals
 Medication Market Overview.svg)
Highlights of The Benign Prostatic Hyperplasia (BPH) Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5-Alpha-Reductase Inhibitors
- Beta-Blockers
- Botanicals and Traditional Chinese Medicine
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Benign Prostatic Hyperplasia (BPH) Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Medication Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Benign Prostatic Hyperplasia (BPH) medication is a type of medicine that is used to treat BPH. This medication helps to reduce the size of the prostate gland and improve symptoms related to BPH.
Some of the key players operating in the benign prostatic hyperplasia (bph) medication market are Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Bayer HealthCare, Bristol-Myers Squibb, Valeant Pharmaceuticals, Endo Pharmaceuticals, Foresee Pharmaceuticals, Merck, Novartis, Advaxis, Teva Pharmaceutical Industries, Urologixs, Agennix, ANI Pharmaceuticals, BHR Pharma, Boehringer Ingelheim, Sanpower Group, Eisai, Ferring, IO THERAPEUTICS, LIDDS, Madrigal Pharmaceuticals, Nymox Pharmaceutical, Spectrum Pharmaceuticals, Takeda Pharmaceuticals.
The benign prostatic hyperplasia (bph) medication market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Benign Prostatic Hyperplasia (BPH) Medication Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Benign Prostatic Hyperplasia (BPH) Medication Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Benign Prostatic Hyperplasia (BPH) Medication Market - Supply Chain
4.5. Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast
4.5.1. Benign Prostatic Hyperplasia (BPH) Medication Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Benign Prostatic Hyperplasia (BPH) Medication Market Size (000 Units) and Y-o-Y Growth
4.5.3. Benign Prostatic Hyperplasia (BPH) Medication Market Absolute $ Opportunity
5. Global Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Type
5.3.1. 5-Alpha-Reductase Inhibitors
5.3.2. Beta-Blockers
5.3.3. Botanicals and Traditional Chinese Medicine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Benign Prostatic Hyperplasia (BPH) Medication Demand Share Forecast, 2019-2026
9. North America Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Type
9.7.1. 5-Alpha-Reductase Inhibitors
9.7.2. Beta-Blockers
9.7.3. Botanicals and Traditional Chinese Medicine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Benign Prostatic Hyperplasia (BPH) Medication Demand Share Forecast, 2019-2026
10. Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Type
10.7.1. 5-Alpha-Reductase Inhibitors
10.7.2. Beta-Blockers
10.7.3. Botanicals and Traditional Chinese Medicine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Benign Prostatic Hyperplasia (BPH) Medication Demand Share Forecast, 2019-2026
11. Europe Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Type
11.7.1. 5-Alpha-Reductase Inhibitors
11.7.2. Beta-Blockers
11.7.3. Botanicals and Traditional Chinese Medicine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Benign Prostatic Hyperplasia (BPH) Medication Demand Share, 2019-2026
12. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Type
12.7.1. 5-Alpha-Reductase Inhibitors
12.7.2. Beta-Blockers
12.7.3. Botanicals and Traditional Chinese Medicine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Demand Share, 2019-2026
13. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size and Volume Forecast by Type
13.7.1. 5-Alpha-Reductase Inhibitors
13.7.2. Beta-Blockers
13.7.3. Botanicals and Traditional Chinese Medicine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Market Share Analysis
14.2. Benign Prostatic Hyperplasia (BPH) Medication Distributors and Customers
14.3. Benign Prostatic Hyperplasia (BPH) Medication Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Astellas Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ADC Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bayer HealthCare
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bristol-Myers Squibb
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Valeant Pharmaceuticals
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Endo Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Foresee Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Merck
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Novartis
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Advaxis
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Teva Pharmaceutical Industries
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Urologixs
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Agennix
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. ANI Pharmaceuticals
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. BHR Pharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Boehringer Ingelheim
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Sanpower Group
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
